NSRXNYSEPharmaceutical PreparationsFiscal year ends December 31
Nasus Pharma Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 25, 2026
$3.21+0.02 (+0.79%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$4.63 (−59.07%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Nasus Pharma Ltd reported revenue of $1.24B for fiscal 2025. Free cash flow was -$4.93M.
Revenue
$1.24B
FY2025
Operating income
-$4.90M
FY2025
Free cash flow
-$4.93M
FY2025
EPS, diluted
-$0.72
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $1.24B
- Net income
- -$5.86M
- EPS, diluted
- -$0.72
- Free cash flow
- -$4.93M
Four years at a glance
Fiscal years 2022 to 2025, USD
Revenue
$1.24B
Operating income
-$4.90M
Net income
-$5.86M
EPS, diluted
-$0.72
Free cash flow
-$4.93M
Reported period